MedTrace Logo

Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis

NCT02945657 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2018-11-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the pharmacokinetic parameters and safety of topical MM36 (OPA-15406) ointment in pediatric subjects with atopic dermatitis under maximal use conditions.

Conditions

Interventions

DRUG

MM36 topical ointment, 1%

Twice daily application for 28 consecutive days

Sponsors & Collaborators

  • Medimetriks Pharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • Noah Rosenberg, MD · Medimetriks Pharmaceuticals, Inc

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2017-06-08
Completion
2017-06-08

Countries

  • United States
  • Honduras
  • Panama

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02945657 on ClinicalTrials.gov